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EDITORIAL
Longevity of biventricular defibrillators: not all
devices are created equal
Haran Burri*
Electrophysiology Unit, Cardiology Service, University Hospital of Geneva, Rue Gabrielle Perret Gentil 4, Geneva 14 1211, Switzerland
This editorial refers to ‘Longevity of implantable cardiover-
ter-defibrillators for cardiac resynchronization therapy in
current clinical practice: an analysis according to influen-
cing factors, device generation, and manufacturer’ by
M. Landolina et al., on page 1251–1258.
The biomedical industry has been facing a technological challenge
for developing cardiac resynchronization therapy-defibrillators
(CRT-Ds) because of the multiple requirements involving power
supply and consumption. The batteries need to provide low-voltage
output for frequent pacing, while being able to rapidly charge capa-
citors to deliver high-power shocks. The cells need to be efficient
and have a high energy density in order to minimize the total volume
of the generator, which are amongst the bulkiest of all cardiac im-
plantable electronic devices (CIEDs). Discharge profiles need to
be consistent in order to predict elective replacement and
end-of-life. Demands on power consumption have been increasing
as the complexity of device functions has been evolving, now includ-
ing a number of diagnostic and telemetric functions. Production
costs need to be contained, without compromising the quality
and reliability of this life-saving therapy.
As indications for CRT-D have broadened to include patients
with mild heart failure,1 life expectancy of this population has out-
grown that of the devices they are implanted with. In the
MADIT-CRT (Multicenter Automatic Defibrillator Implantation
Trial with Cardiac Resynchronization Therapy) trial, which included
patients with NYHA I-II heart failure, 7-year survival in patients with
left bundle branch block randomized to the CRT-D group was
82%.2 If one assumes that CRT-D device longevity is 5 years, 88%
of this patient population would have to undergo a generator re-
placement. This procedure is associated with major complications
in 6% of the patients, which is greater than that observed with
single- and dual-chamber devices.3 Costs are evidently affected
by device longevity. Boriani et al.4 calculated that extending
CRT-D longevity from 4 to 7 years would result in a total cost sav-
ing of E10 968–E13 630 per patient. Last but not least, the vast
majority of patients (90% overall) prefer a larger device with great-
er longevity over a smaller and less noticeable one in order to avoid
generator replacements.5 This preference was consistent over the
entire spectrum of patients of different ages, gender, and body
habitus.
A list of potential factors that may affect device longevity is out-
lined in Table 1. Important factors are battery capacity and discharge
characteristics. All modern CIED batteries are composed of a lith-
ium anode with different cathode chemistries. The first implantable
cardioverter-defibrillator (ICD) batteries were composed of lith-
ium–vanadium pentoxide, and were later replaced by the more re-
liable lithium–silver vanadium oxide (Li/SVO) battery developed by
Greatbatch Inc. (Clarence, NY, USA) which enabled the growth of
this technology. Hybrid batteries combining Li/SVO and carbon
monofluoride (CFx), either blended together in a single mixture
or as a laminated structure (the SVO and CFx cathodes being sepa-
rated by screens), have replaced the Li/SVO batteries for CRT-Ds
due to greater longevity. Another battery chemistry that is also cur-
rently in use is lithium manganese dioxide (Li/MnO2), which has a
high energy density and excellent storage and discharge character-
istics. These batteries are produced in-house by the device compan-
ies (Biotronik and Boston Scientific), contrary to the Li/SVO and Li/
SVO–CFx (also known as QHR) batteries that are supplied by
Greatbatch Inc. An excellent review on CIED battery technology
has recently been published by Mond and Freitag6 for those readers
who wish to dig deeper into this topic.
In this issue of Europace, Landolina et al.7 report CRT-D longevity
in 1726 consecutive patients (the largest series reported to date)
implanted between January 2008 and March 2010 in nine Italian cen-
tres. The report includes devices from the five major companies re-
leased onto the market from 2003 to 2010 and followed-up over a
median of 43 months. Five years after implantation, almost half
(46%) of the devices needed to be replaced due to battery deple-
tion. Factors found to independently affect device longevity were:
– A high (.2.5 V/0.5 ms) left ventricular (LV) lead pacing output
which adversely affected longevity (HR: 1.96; 95% CI: 1.57–
2.46; P, 0.001). A trend in reduced longevity was found for
a high right ventricular (RV) output, which did not reach statis-
tical significance due to the small numbers involved (,5% of
patients with a high output compared with 24% of patients
for the LV lead). A high atrial output did not affect longevity,
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because atrial pacing is usually infrequent in these patients and
will therefore have a minor impact.
– A unipolar LV lead, corresponding to an extended bipolar (LV tip
to RV coil) or unipolar pacing configuration (HR: 1.58, 95% CI:
1.25–2.01; P, 0.001). Unipolar pacing (LV to can) is currently
only possible with Boston Scientific CRT-Ds. This finding can be
explained by lower impedances with these configurations com-
pared with true bipolar pacing, thus adversely affecting current
drain (remember Ohm’s law: I ¼ V/R).
– Battery chemistry with greater longevity of Li/SVO–CFx (HR:
0.28, 95% CI: 0.16–0.50, P, 0.001) or Li/MgO2 (HR: 0.37,
95% CI: 0.22–0.64, P, 0.001) compared with Li/SVO.
– Recent generation devices, i.e. released after 2007 (HR: 0.57, 95%
CI: 0.45–0.72; P, 0.001). This finding was consistent across
the different manufacturers (the numbers were however too
small for analysing Biotronik devices). The differences reflect
not only changes in battery chemistry (e.g. adoption of Li/
MgO2 batteries by Boston Scientific) but also a change in bat-
tery models using the same chemistry (e.g. St Jude Medical),
and the advent of threshold algorithms that automatically adjust
LV output, allowing lower safety margins (Medtronic and St Jude
Medical).
– Device manufacturer, with Boston Scientific CRT-Ds displaying
greatest longevity (HR: 0.64; 95% CI: 0.47–0.89; P ¼ 0.008).
This finding was essentially due to a change in the battery
chemistry, as none of the devices from this manufacturer had
automatic LV output algorithms at the time of the study. The
considerable extension in longevity of the recent generation
Boston Scientific CRT-Ds has prompted the manufacturer to
extend the 100% replacement warranty on their latest devices
from 3 to 4 years, which is the longest currently available.
A factor that did not affect longevity was delivery of shocks. This may
seem surprising but was probably due to the fact that very few pa-
tients received frequent shocks (only 3% of the cohort received
.10 shocks over the entire follow-up). Another consideration is
that the delivery of a shock will reset the timer for the next capacitor
reforming (which equates to a full capacitor charge and is performed
nominally every 3–6 months), thereby limiting the total number of
capacitor charges. For most manufacturers, resetting of the
capacitor charge timer only occurs if shocks are programmed to
full (or close to full) energy. This is one of the reasons to avoid pro-
gramming lower energy shocks (e.g. 15J), especially as pain to the pa-
tient will be the same (another reason being a lower probability of
atrial cardioversion in case of inappropriate shock due to rapidly
conducted atrial fibrillation).
It is surprising that none of the patients in this large multicentre
cohort were placed on remote device management. In the ECOST
(Effectiveness and Cost of ICDs Follow-up Schedule with Telecar-
diology) trial, patients implanted with a single- or dual-chamber
ICD who were randomized to the remote monitoring group had
significantly fewer inappropriate shocks, resulting in prolonged de-
vice longevity.8 Remote monitoring may also allow the physician
to more confidently extend generator replacement until the elect-
ive replacement indicator is reached, triggering transmission of an
alert message (the audible alerts being often unreliable9). On the
other hand, depending upon the device manufacturer, frequent
transmissions may cause an excessive current drain on the battery
that may have an adverse effect on longevity.
The findings published in this issue confirm a recent report by
Alam et al.10 in 646 patients implanted with a CRT-D during a similar
period. Longevity was also significantly affected by LV pacing output
and by the device manufacturer. The 4-year device survival rate
was 94% for Boston Scientific, 92% for St Jude Medical, and 67%
for Medtronic (P, 0.001). The results for CRT-D devices are in
contrast to those reported for single- and dual-chamber ICDs,
where Medtronic devices outlived those of the other manufac-
turers.11 –13 This finding illustrates the complexity resulting from
the specific requirements of CRT-Ds. The current generation of
Medtronic CRT-Ds has evolved considerably from a technological
standpoint, which is likely to have a favourable effect on device lon-
gevity. The Li/SVO battery has been replaced by a Li/SVO–CFx
model. The new wet Tantalum capacitors (now also used by other
manufacturers) do not require reforming anymore (which drains
almost 1 month of device life with each charge). Quadripolar LV
leads allow more options to lower capture thresholds, with 95%
of patients having thresholds ≤2.5 V without phrenic nerve capture,
and average thresholds of the programmed vector being 1.1+
0.8 V.14 An algorithm has been introduced which automatically
measures thresholds and impedances of each of the 16 vectors.
The device then calculates the estimated gain in longevity with
each vector, thereby allowing programming to optimize battery
consumption. Finally, an algorithm designed to promote fusion
pacing (between intrinsic AV conduction and left univentricular
capture) to improve haemodynamics, means that the percentage
of RV pacing will be reduced, thereby reducing current drain. Future
reports will be of interest to determine the impact of these changes
on CRT-D longevity of Medtronic devices.
In addition to the favourable effect on patient outcome and
healthcare costs, improved longevity is also an important factor
which is taken into account by physicians and hospital purchasing
departments for choosing devices. This has a positive impact on
market share of manufacturers proposing durable devices. How-
ever, the commercial return may be mitigated in the long run by a
reduction in the turnover of generator replacements, which, com-
bined with the global pressure on prices, is likely to result in reduced
income for the companies. The CIED industry has, however, proved
Table 1 Factors affecting ICD/CRT-D longevity
Battery characteristics (size, chemistry, energy density, self-discharge,
etc.)
Numbers of shocks
Frequency of battery reforming
Consumption of electrical circuitry (‘housekeeping current’)
Numbers of pacing leads (and multipoint pacing)
Percentage of pacing
Lead impedance
Pacing output (amplitude and duration)
Device algorithms and memory storage
Physiological sensors
Remote monitoring
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itself in the past to react remarkably well when faced with chal-
lenges. Natural market selection and survival of the fittest device
will lead to evolution of therapy that will ultimately benefit our
patients.
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